318 related articles for article (PubMed ID: 30698318)
1. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis.
Ko SW; Kim YJ; Chung WC; Lee SJ
Helicobacter; 2019 Apr; 24(2):e12565. PubMed ID: 30698318
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of second-line regimens for
Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
[TBL] [Abstract][Full Text] [Related]
3. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
Lu B; Wang J; Li J; Liu L; Chen Y
Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
[TBL] [Abstract][Full Text] [Related]
4. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis.
Han Z; Li Y; Kong Q; Liu J; Wang J; Wan M; Lin M; Lin B; Zhang W; Ding Y; Wang S; Mu Y; Duan M; Zuo X; Li YQ
Helicobacter; 2022 Dec; 27(6):e12930. PubMed ID: 36156332
[TBL] [Abstract][Full Text] [Related]
6. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
[TBL] [Abstract][Full Text] [Related]
7. Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study.
Romano M; Gravina AG; Nardone G; Federico A; Dallio M; Martorano M; Mucherino C; Romiti A; Avallone L; Granata L; Priadko K; Compare D; Tuccillo C; Romito MR; Sgambato D; Miranda A; Romano L; Loguercio C; Bazzoli F; Zagari RM
Helicobacter; 2020 Aug; 25(4):e12694. PubMed ID: 32314519
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
[TBL] [Abstract][Full Text] [Related]
9. Role of Bismuth in the Eradication of Helicobacter pylori.
Alkim H; Koksal AR; Boga S; Sen I; Alkim C
Am J Ther; 2017; 24(6):e751-e757. PubMed ID: 26808355
[TBL] [Abstract][Full Text] [Related]
10. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection.
Kim YJ; Chung WC; Kim DB
Helicobacter; 2021 Jun; 26(3):e12792. PubMed ID: 33650225
[TBL] [Abstract][Full Text] [Related]
12. Tailored eradication
Choi YI; Chung JW; Park DK; Kim KO; Kwon KA; Kim YJ; Seo JY
World J Gastroenterol; 2019 Dec; 25(46):6743-6751. PubMed ID: 31857776
[TBL] [Abstract][Full Text] [Related]
13. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
14. Development of
Suzuki S; Esaki M; Kusano C; Ikehara H; Gotoda T
World J Gastroenterol; 2019 Apr; 25(16):1907-1912. PubMed ID: 31086459
[No Abstract] [Full Text] [Related]
15. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
Zhou L; Zhang J; Song Z; He L; Li Y; Qian J; Bai P; Xue Y; Wang Y; Lin S
Helicobacter; 2016 Apr; 21(2):91-9. PubMed ID: 26104022
[TBL] [Abstract][Full Text] [Related]
16. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori.
Nyssen OP; McNicholl AG; Gisbert JP
Helicobacter; 2019 Apr; 24(2):e12570. PubMed ID: 30767339
[TBL] [Abstract][Full Text] [Related]
18. [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of
Zhang M; Chen CY; Wang XT; Lyu B
Zhonghua Nei Ke Za Zhi; 2017 May; 56(5):368-374. PubMed ID: 28460509
[No Abstract] [Full Text] [Related]
19. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
Zhang YW; Hu WL; Cai Y; Zheng WF; Du Q; Kim JJ; Kao JY; Dai N; Si JM
World J Gastroenterol; 2018 Oct; 24(40):4596-4605. PubMed ID: 30386109
[TBL] [Abstract][Full Text] [Related]
20. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.
Basyigit S; Kefeli A; Sapmaz F; Yeniova AO; Asilturk Z; Hokkaomeroglu M; Uzman M; Nazligul Y
Bosn J Basic Med Sci; 2015 Oct; 15(4):50-4. PubMed ID: 26614852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
